In this phase 1 , open-label study , patients with active RA were randomized to receive s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 ( n = 33 ; group 1 ) or i.v. golimumab 2 mg/kg at baseline and week 12 ( n = 16 ; group 2 ) .
